Skip to main content

Table 2 Predictors of SALL4 immunoreactivity in hepatocellular carcinomas

From: Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma

Univariate analysis

  

Variable

Odds Ratio (95% CI)

P

HBV

3.240 (1.690-6.200)

<0.001

HCV

0.585 (0.314-1.090)

0.091

Diabetes mellitus

0.384 (0.157-0.940)

0.036

History of alcohol intakea

0.367 (0.140-0.964)

0.041

Body mass index≥25 (kg/m2)

0.249 (0.056-1.110)

0.068

Preoperative treatmentb

0.958 (0.509-1.810)

0.895

Liver cirrhosis

1.170 (0.623-2.200)

0.626

Background Steatosisc

0.434 (0.202-0.933)

0.032

Multivariate analysis

  

Variable

Odds Ratio (95% CI)

P

HBV

3.110 (1.590-6.070)

<0.001

Diabetes mellitus

0.474 (0.189-1.190)

0.112

History of alcohol intakea

0.436 (0.162-1.170)

0.099

Background steatosisc

0.437 (0.199-0.963)

0.039

  1. HBV, hepatitis B virus; HCV, hepatitis C virus.
  2. Significant P-values are indicated in bold.
  3. aIntake of 80 g or more of alcohol per day.
  4. bPreoperative treatment included transcatheter arterial embolization, transcatheter arterial infusion chemotherapy, transcatheter arterial chemoembolization, or portal embolization.
  5. cSteatosis in 5% or more of hepatocytes.